Overview

A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker. This study has two treatment periods. Participants will receive tadalafil or placebo in each treatment period.

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Collaborators:

Nippon Shinyaku Co Ltd
Nippon Shinyaku Co., Ltd.

Treatments:

Tadalafil